Stockholders' Deficiency (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Series A Convertible preferred stock, shares available to be issued	44,443	44,443
Selling, General And Administrative Expenses	$ 135,000	$ 15,000
Stock-based compensation expense, unamortized	$ 320,366	$ 830,518
Stock Option [Member]
Option grants at a weighted average annual rate	3.00%	4.00%
Weighted Average Fair Value	$ 0.10	$ 0.16
Selling, General And Administrative Expenses	$ 308,026	$ 698,015
Stock-based compensation expense, unamortized	1,033,764
Stock-based compensation expense, amortized	$ 142,195
Weighted Average Remaining Period	2 years
Performance based option vesting	$ 891,569
Warrant [Member]
Weighted Average Fair Value	$ 0.09	$ 0.20
Selling, General And Administrative Expenses	$ 12,340	$ 132,503
Stock-based compensation expense, unamortized	$ 576,840
Stock-based compensation expense, amortized
Performance based option vesting	$ 576,840
Common stock purchased	137,430
Aggregate grant date value	$ 27,486
Common stock issued	97,449
Series B Preferred Stock [Member]
Converted shares	11.39
Beneficial Conversion Feature Related to Incremental Shares	3,089,642
Preferred Stock Contractual Dividends	319,854	298,918
Employees And Directors [Member]
Common stock purchased	2,141,339
Aggregate grant date value	$ 211,860
Consultants [Member]
Selling, General And Administrative Expenses	$ 322
Common stock purchased	349,861
Aggregate grant date value	$ 37,423